胰高血糖素样肽-1及其类似物保护认知功能的研究进展

背景 认知功能障碍是指学习记忆、思维判断等大脑高级功能异常,目前尚无确切的防治药物.2型糖尿病被公认为发生认知功能障碍的危险因素.胰高血糖素样肽-1（glucagon-like peptide-1,GLP-1）及其类似物是一种针对2型糖尿病的新型降糖药,研究发现其还具有保护认知功能的作用. 目的 为GLP-1及其类似物应用于临床防治认知功能障碍提供理论依据. 内容 就GLP-1及其类似物的保护认知功能的研究现状作一综述. 趋向 有望成为防治认知功能障碍等神经病理性疾病的新型药物.     

儿童肾病综合征血清C肽和胰岛素样生长因子变化及意义

具有类似于生长激素和胰岛素作用的胰岛素样生长因子 (IGFs) ,其由IGF -Ⅰ、IGF -Ⅱ及其受体、系列结合蛋白组成。C -肽 (CP)由胰腺 β细胞释放的 ,经胰岛素原转化酶分解成 ,近期研究表明 ,这些因子在机体的营养代谢中起重要作用[1,2 ] 。本文探索肾病综合征 (PNS)患儿血清CP、IGF-Ⅰ、IGF -Ⅱ的水平及意义。资料与方法1　一般资料　 1999年 1月～ 2 0 0 1年 6月在本院儿科住院的患儿共 2 8例 ,诊断符合全国小儿肾脏病协作组制定的原发性肾病综合征 (PNS)的诊断标准。初发组 13例 ,男10例 ,女 3例 ;年龄 5岁～ 10岁 ,平均 (6 .6…     

生长激素促进烫伤鼠肝、创面组织胰岛素样生长因子-Ⅰ及其结合蛋白-3 mRNA的表达

目的　研究重组生长激素 (rhGH)在促进创面愈合过程中对烫伤大鼠肝、创面组织胰岛素样生长因子 Ⅰ (IGF Ⅰ ) /胰岛素样生长因子结合蛋白 3(IGFBP 3)mRNA表达的影响。方法制作大鼠深Ⅱ度烫伤模型 ,每日早上 9点皮下注射rhGH 0 .3IU/d ,疗程 1 0d。逆转录 聚合酶链反应 (RT PCR)检测肝、创面组织IGF Ⅰ /IGFBP 3mRNA表达 ;酶联免疫吸附试验 (ELISA)检测血IGF Ⅰ /IGFBP 3浓度 ;免疫组织化学检测Ⅰ、Ⅲ型胶原的表达。结果　用rhGH治疗 1 0d ,烫伤大鼠肝、创面组织IGF Ⅰ /IGFBP 3mRNA的表达、血IGF Ⅰ的水平较对照组明显升高 (P <0 .0 1 ) ;Ⅰ、Ⅲ型胶原的含量较对照组明显增多 (P <0 .0 1 ) ;而创面愈合时间平均提前 3d。结论　rhGH可通过增加肝、创面组织IGF Ⅰ /IGFBP 3mRNA的表达 ,促进创面愈合。     

胰岛素和胰岛素样生长因子及其结合蛋白与结直肠癌发生的关系

目的探讨血清胰岛素、胰岛素样生长因子（IGF-1）、IGF结合蛋白（IGFBPs）体质量指数（BMI）、腰臀围比（WHR）的变化及与结直肠癌发生、发展的关系。方法检测对象为2006年6月至2007年10月间住院收治和门诊复查的结直肠癌患者615例（术前检测244例,术后371例）和健康对照者150例。采用酶联免疫吸附法检测血清胰岛素、IGF-1和IGFBPS水平。结果结直肠癌患者术前血清胰岛素、IGF-1水平和IGF-I／IGFBP-3比值与健康对照组、术后患者比较,均明显升高,IGFBP-3水平明显降低,差异均有统计学意义（P〈0.05,P〈0.01）。结直肠癌术后未发生转移者与有肝或腹腔远处转移者胰岛素、IGF-1、IGFBP-1、IGFBP-3、IGF-1／IGFBP-3比较,差异均无统计学意义（P〉0.05）。结直肠癌患者WHR明显高于健康对照组（P〈0.01和P〈0.05）;而BMI与健康对照组比较,差异无统计学意义（P〉0.05）。结肠癌患者WHR、BMI与胰岛素水平、IGF-1／IGFBP-3比值呈正相关（P〈0.01,P〈0.05）,与IGFBP-3呈负相关（P〈0.01,P〈0.05）;直肠癌患者WHR与血清瘦素、胰岛素水平及BMI与血清IGFBP-1水平均呈正相关（P〈0.05）,与其他无相关性（P〉0.05）。结论胰岛素、IGF-1水平和IGF-I／IGFBP-3比值升高及IGFBP-3水平降低,可能与结直肠癌的发生有关,但与肿瘤转移与否无关,中心性肥胖是结肠癌发生的危险因素之一。     

胰岛素和胰岛素样生长因子及其结合蛋白与结直肠癌发生的关系

目的 探讨血清胰岛素、胰岛素样生长因子(IGF-1)、IGF结合蛋白(IGFBPs)及体质量指数(BMI)、腰臀围比(WHR)的变化及与结直肠癌发生、发展的关系.方法 检测对象为2006年6月至2007年10月间住院收治和门诊复查的结直肠癌患者615例(术前检测244例,术后371例)和健康对照者150例.采用酶联免疫吸附法检测血清胰岛素、IGF-1和IGFBPS水平.结果 结直肠癌患者术前血清胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值与健康对照组、术后患者比较,均明显升高,IGFBP-3水平明显降低,差异均有统计学意义(P<0.05,P<0.01).结直肠癌术后未发生转移者与有肝或腹腔远处转移者胰岛素、IGF-1、IGFBP-1、IGFBP-3、IGF-1/IGFBP-3比较.差异均无统计学意义(P>0.05).结直肠癌患者WHR明显高于健康对照组(P<0.01和P<0.05):而BMI与健康对照组比较,差异无统计学意义(P>0.05).结肠癌患者WHR、BMI与胰岛素水平、IGF-1/IGFBP-3比值呈正相关(P<0.01,P<0.05),与IGFBP-3呈负相关(P<0.01,P<0.05);直肠癌患者WHR与血清瘦素、胰岛素水平及BMI与血清IGFBP-1水平均呈正相关(P<0.05),与其他无相关性(P>0.05).结论 胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值升高及IGFBP-3水平降低,可能与结直肠癌的发生有关,但与肿瘤转移与否无关,中心性肥胖是结肠癌发生的危险因素之一.     

胰岛素和胰岛素样生长因子及其结合蛋白与结直肠癌发生的关系

目的 探讨血清胰岛素、胰岛素样生长因子(IGF-1)、IGF结合蛋白(IGFBPs)及体质量指数(BMI)、腰臀围比(WHR)的变化及与结直肠癌发生、发展的关系.方法 检测对象为2006年6月至2007年10月间住院收治和门诊复查的结直肠癌患者615例(术前检测244例,术后371例)和健康对照者150例.采用酶联免疫吸附法检测血清胰岛素、IGF-1和IGFBPS水平.结果 结直肠癌患者术前血清胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值与健康对照组、术后患者比较,均明显升高,IGFBP-3水平明显降低,差异均有统计学意义(P<0.05,P<0.01).结直肠癌术后未发生转移者与有肝或腹腔远处转移者胰岛素、IGF-1、IGFBP-1、IGFBP-3、IGF-1/IGFBP-3比较.差异均无统计学意义(P>0.05).结直肠癌患者WHR明显高于健康对照组(P<0.01和P<0.05):而BMI与健康对照组比较,差异无统计学意义(P>0.05).结肠癌患者WHR、BMI与胰岛素水平、IGF-1/IGFBP-3比值呈正相关(P<0.01,P<0.05),与IGFBP-3呈负相关(P<0.01,P<0.05);直肠癌患者WHR与血清瘦素、胰岛素水平及BMI与血清IGFBP-1水平均呈正相关(P<0.05),与其他无相关性(P>0.05).结论 胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值升高及IGFBP-3水平降低,可能与结直肠癌的发生有关,但与肿瘤转移与否无关,中心性肥胖是结肠癌发生的危险因素之一.     

胰岛素和胰岛素样生长因子及其结合蛋白与结直肠癌发生的关系

目的 探讨血清胰岛素、胰岛素样生长因子(IGF-1)、IGF结合蛋白(IGFBPs)及体质量指数(BMI)、腰臀围比(WHR)的变化及与结直肠癌发生、发展的关系.方法 检测对象为2006年6月至2007年10月间住院收治和门诊复查的结直肠癌患者615例(术前检测244例,术后371例)和健康对照者150例.采用酶联免疫吸附法检测血清胰岛素、IGF-1和IGFBPS水平.结果 结直肠癌患者术前血清胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值与健康对照组、术后患者比较,均明显升高,IGFBP-3水平明显降低,差异均有统计学意义(P<0.05,P<0.01).结直肠癌术后未发生转移者与有肝或腹腔远处转移者胰岛素、IGF-1、IGFBP-1、IGFBP-3、IGF-1/IGFBP-3比较.差异均无统计学意义(P>0.05).结直肠癌患者WHR明显高于健康对照组(P<0.01和P<0.05):而BMI与健康对照组比较,差异无统计学意义(P>0.05).结肠癌患者WHR、BMI与胰岛素水平、IGF-1/IGFBP-3比值呈正相关(P<0.01,P<0.05),与IGFBP-3呈负相关(P<0.01,P<0.05);直肠癌患者WHR与血清瘦素、胰岛素水平及BMI与血清IGFBP-1水平均呈正相关(P<0.05),与其他无相关性(P>0.05).结论 胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值升高及IGFBP-3水平降低,可能与结直肠癌的发生有关,但与肿瘤转移与否无关,中心性肥胖是结肠癌发生的危险因素之一.     

胰岛素和胰岛素样生长因子及其结合蛋白与结直肠癌发生的关系

目的 探讨血清胰岛素、胰岛素样生长因子(IGF-1)、IGF结合蛋白(IGFBPs)及体质量指数(BMI)、腰臀围比(WHR)的变化及与结直肠癌发生、发展的关系.方法 检测对象为2006年6月至2007年10月间住院收治和门诊复查的结直肠癌患者615例(术前检测244例,术后371例)和健康对照者150例.采用酶联免疫吸附法检测血清胰岛素、IGF-1和IGFBPS水平.结果 结直肠癌患者术前血清胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值与健康对照组、术后患者比较,均明显升高,IGFBP-3水平明显降低,差异均有统计学意义(P<0.05,P<0.01).结直肠癌术后未发生转移者与有肝或腹腔远处转移者胰岛素、IGF-1、IGFBP-1、IGFBP-3、IGF-1/IGFBP-3比较.差异均无统计学意义(P>0.05).结直肠癌患者WHR明显高于健康对照组(P<0.01和P<0.05):而BMI与健康对照组比较,差异无统计学意义(P>0.05).结肠癌患者WHR、BMI与胰岛素水平、IGF-1/IGFBP-3比值呈正相关(P<0.01,P<0.05),与IGFBP-3呈负相关(P<0.01,P<0.05);直肠癌患者WHR与血清瘦素、胰岛素水平及BMI与血清IGFBP-1水平均呈正相关(P<0.05),与其他无相关性(P>0.05).结论 胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值升高及IGFBP-3水平降低,可能与结直肠癌的发生有关,但与肿瘤转移与否无关,中心性肥胖是结肠癌发生的危险因素之一.     

胰岛素和胰岛素样生长因子及其结合蛋白与结直肠癌发生的关系

目的 探讨血清胰岛素、胰岛素样生长因子(IGF-1)、IGF结合蛋白(IGFBPs)及体质量指数(BMI)、腰臀围比(WHR)的变化及与结直肠癌发生、发展的关系.方法 检测对象为2006年6月至2007年10月间住院收治和门诊复查的结直肠癌患者615例(术前检测244例,术后371例)和健康对照者150例.采用酶联免疫吸附法检测血清胰岛素、IGF-1和IGFBPS水平.结果 结直肠癌患者术前血清胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值与健康对照组、术后患者比较,均明显升高,IGFBP-3水平明显降低,差异均有统计学意义(P<0.05,P<0.01).结直肠癌术后未发生转移者与有肝或腹腔远处转移者胰岛素、IGF-1、IGFBP-1、IGFBP-3、IGF-1/IGFBP-3比较.差异均无统计学意义(P>0.05).结直肠癌患者WHR明显高于健康对照组(P<0.01和P<0.05):而BMI与健康对照组比较,差异无统计学意义(P>0.05).结肠癌患者WHR、BMI与胰岛素水平、IGF-1/IGFBP-3比值呈正相关(P<0.01,P<0.05),与IGFBP-3呈负相关(P<0.01,P<0.05);直肠癌患者WHR与血清瘦素、胰岛素水平及BMI与血清IGFBP-1水平均呈正相关(P<0.05),与其他无相关性(P>0.05).结论 胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值升高及IGFBP-3水平降低,可能与结直肠癌的发生有关,但与肿瘤转移与否无关,中心性肥胖是结肠癌发生的危险因素之一.     

胰岛素和胰岛素样生长因子及其结合蛋白与结直肠癌发生的关系

目的 探讨血清胰岛素、胰岛素样生长因子(IGF-1)、IGF结合蛋白(IGFBPs)及体质量指数(BMI)、腰臀围比(WHR)的变化及与结直肠癌发生、发展的关系.方法 检测对象为2006年6月至2007年10月间住院收治和门诊复查的结直肠癌患者615例(术前检测244例,术后371例)和健康对照者150例.采用酶联免疫吸附法检测血清胰岛素、IGF-1和IGFBPS水平.结果 结直肠癌患者术前血清胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值与健康对照组、术后患者比较,均明显升高,IGFBP-3水平明显降低,差异均有统计学意义(P<0.05,P<0.01).结直肠癌术后未发生转移者与有肝或腹腔远处转移者胰岛素、IGF-1、IGFBP-1、IGFBP-3、IGF-1/IGFBP-3比较.差异均无统计学意义(P>0.05).结直肠癌患者WHR明显高于健康对照组(P<0.01和P<0.05):而BMI与健康对照组比较,差异无统计学意义(P>0.05).结肠癌患者WHR、BMI与胰岛素水平、IGF-1/IGFBP-3比值呈正相关(P<0.01,P<0.05),与IGFBP-3呈负相关(P<0.01,P<0.05);直肠癌患者WHR与血清瘦素、胰岛素水平及BMI与血清IGFBP-1水平均呈正相关(P<0.05),与其他无相关性(P>0.05).结论 胰岛素、IGF-1水平和IGF-Ⅰ/IGFBP-3比值升高及IGFBP-3水平降低,可能与结直肠癌的发生有关,但与肿瘤转移与否无关,中心性肥胖是结肠癌发生的危险因素之一.     

Circulating levels of insulin-like growth factor binding protein 3 (IGFBP-3) and insulin-like growth factor I (IGF-I) in perimenopausal women

The study investigated possible menopause-related changes in circulating insulin-like growth factor binding protein 3 (IGFBP-3) levels and their relationship with insulin-like growth factor I (IGF-I) plasma levels. Forty-three healthy women, aged 45–55 years, were studied (22 premenopausal and 21 postmeno-pausal, matched for age and body mass index); in all subjects plasma IGF-I and IGFBP-3 levels were measured by radioimmunoassay. No difference was found between mean IGFBP-3 plasma levels in the two groups studied (premenopausal 3.42±0.49 v postmenopausal 3.46±0.58 mg/l), while mean IGF-I levels were significantly lower in postmenopausal as compared with premenopausal women (136.7±37.86 v 175.7±51.91 ng/ml,p<0.02). Multiple regression analysis showed no significant effect of age, body mass index and years since menopause on IGFBP-3 levels; however, considering the IGF-I/IGFBP-3 ratio as a possible parameter of circulating free somatomedin C, an inverse correlation was found with years since menopause (n=43,r=–0.499,p<0.001). We conclude that lack of oestrogen induces different effects on circulating IGF-I and IGFBP-3, possibly reflecting a real decrease in IGF-I activity.     

Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer

High circulating insulin-like growth factor 1 (IGF-1) levels are firmly established as a risk factor for developing breast cancer, especially estrogen positive tumors. The effect of circulating IGF-1 on prognosis once a tumor is established is unknown. The authors explored the effect of IGF-1 blood levels and of it's main binding protein, IGFBP-3, on overall survival and occurrence of second primary breast tumors in breast cancer patients, as well as reproductive and lifestyle factors that could modify this risk. Patients were accrued from six hospitals in the Netherlands between 1998 and 2003. Total IGF-1 and IGFBP-3 were measured in 582 plasma samples.No significant association between IGF-1 and IGFBP-3 plasma levels and overall survival was found. However, in a multivariate Cox regression model including standard prognostic variables high IGF-1 levels were related to worse overall survival in patients receiving endocrine therapy (HR = 1.37, 95% CI: 1.11, 1.69, P 0.004). These data at least indicate that higher IGF-1 levels, and as a consequence most likely IGF-1-induced signaling, are related to a less favorable overall survival in breast cancer patients treated with endocrine therapy. Interventions aimed at reducing circulating levels of IGF-1 in hormone receptor positive breast cancer may improve survival.     

Insulin-like growth factor-I and insulin-like growth factor-binding proteins in the nephrotic syndrome

Similar to findings in the nephrotic syndrome in humans, rats with the doxorubicin-induced nephrotic syndrome (which resembles minimal change disease) have reduced serum levels of insulin-like growth factor-I (IGF-I). This is mainly caused by glomerular ultrafiltration of IGF-I-containing binding protein complexes, primarily of a molecular weight of approximately 50 kilodaltons, and urinary losses of the peptide. Despite urinary excretion of IGF-binding protein (IGFBP)-2, serum levels are increased more than twofold in the nephrotic syndrome compared with controls, because of increased synthesis of this binding protein by the liver. In contrast, the liver synthesis of IGFBP-3, the predominant binding protein in normal serum, is unchanged in the nephrotic syndrome. However, binding and serum levels of IGFBP-3 are reduced in nephrotic rat serum, apparently due to proteolytic degradation of IGFBP-3. The glomerular ultrafiltration of IGF-I, which leads to biologically significant IGF-I concentrations of about 1.35 nM in proximal tubule fluid, may have metabolic consequences, such as increased tubular phosphate absorption. Hypothetically, tubule fluid IGF-I may also contribute to progressive tubulointerstitial fibrosis which is sometimes present in protractive nephrotic glomerulopathies. The profound changes in the IGF-I/IGFBP system in the nephrotic syndrome may also contribute to systemic metabolic abnormalities and growth failure.     

卵巢癌中胰岛素样生长因子-1及其受体表达与临床病理特征的相关性

目的研究卵巢癌中胰岛素样生长因子-1(insulin like growth factor-1,IGF-1)及其受体IGF-1R表达与临床病理特征、手术预后的相关性。方法采用免疫组化检测卵巢癌、卵巢交界性肿瘤、卵巢良性肿瘤中IGF-1、IGF-1R的阳性表达率,分析IGF-1、IGF-1R与临床病理特征、手术预后的相关性。结果卵巢癌中IGF-1、IGF-1R的阳性表达量率分别为65.63%、70.31%,明显高于卵巢交界性肿瘤中IGF-1、IGF-1R的阳性表达量率22.22%、16.67%及卵巢良性肿瘤中IGF-1、IGF-1R的阳性表达量率5.00%、10.00%(χ^2/P=27.548/0.000、31.335/0.000),IGF-1、IGF-1R的mRNA表达量及蛋白表达量也明显高于卵巢交界性肿瘤及卵巢良性肿瘤(F/P=31.922/0.000、26.865/0.000、34.567/0.000、27.667/0.000);国际妇产科协会(federation international of gynecology and obstetrics,FIGO)III^IV期、组织分化程度G2~G3、CA125≥35 U/ml、Ki67阳性的卵巢癌中IGF-1、IGF-1R的阳性表达率明显高于FIGO I^II期、组织分化程度G1、CA125<35 U/ml、Ki67阴性的卵巢癌(IGF-1的χ^2/P=8.505/0.004、4.980/0.026、7.481/0.006、10.907/0.001;IGF-1R的χ^2/P=9.785/0.002、4.950/0.026、7.211/0.007、6.471/0.011);卵巢癌IGF-1阳性患者的总生存时间较IGF-1阴性患者缩短。结论IGF-1、IGF-1R在卵巢癌中高表达,且与病理特征及手术预后的恶化相关。     

输精管绝育技术的研究历史与进展

以输精管为靶点的节育技术在男性节育中占有重要的地位,多年来研究人员进行了不断地研究和实践,取得了一定的效果。主要包括输精管结扎术、输精管栓堵术、输精管电凝术、输精管内节育装置（IVD）绝育术等,具体操作方法虽有所不同,但均为试图达到绝育效果好、安全性高、并发症少且复通率佳的目的。本综述对输精管绝育技术发展的过去、现在和未来进行了回顾和展望,以期获得新的认识和启示。     

胰岛素样生长因子ⅡmRNA结合蛋白3对胆囊癌迁移侵袭的影响

目的探究胰岛素样生长因子Ⅱ(insulin-like growth factorⅡ,IGF-Ⅱ)mRNA结合蛋白3(IGF2BP3)对胆囊癌迁移侵袭的作用。方法应用实时定量PCR(qRT-PCR)法检测23份胆囊癌组织和23份癌旁组织中IGF2BP3的表达水平;在胆囊癌细胞中利用小干扰RNA(siRNA)敲减目的基因IGF2BP3;Transwell迁移实验与带胶Transwell侵袭实验检测敲减IGF2BP3后对胆囊癌细胞迁移侵袭能力的影响;细胞免疫荧光法检测敲减IGF2BP3后上皮细胞间充质转化(epithelial mesenchymal transition,EMT)相关蛋白表达水平变化。结果 IGF2BP3在胆囊癌组织中高表达(P0.05);与正常胆管上皮细胞比较,5株胆囊癌细胞系中IGF2BP3高表达;敲减IGF2BP3后,胆囊癌细胞系的迁移侵袭能力明显降低(P0.0001);敲减IGF2BP3后EMT相关蛋白表达水平下调。结论 IGF2BP3通过促进EMT,从而促进胆囊癌侵袭转移。     

Insulin-like growth factor-1, growth hormone-dependent insulin-like growth factor-binding protein and growth in children with chronic renal failure

Insulin-like growth factor-binding protein-3 (IGFBP-3) and insulin-like growth factor-1 (IGF-1) levels were measured by specific radioimmunoassays in children with all degrees of chronic renal failure (CRF). Study group 1 comprised 29 children (10 on dialysis) who had been studied one to four times over 2 years to determine whether IGF-1 and IGFBP-3 levels differed from those in age-matched healthy children and to examine the relationship between these levels and heights. IGF-1 and IGFBP-3 levels did not differ from those in normal children. IGF-1 and IGFBP-3 were significantly correlated, increased with pubertal stage in all children and with age in non-dialysis patients. IGF-1, but not IGFBP-3, correlated with age in dialysis patients. There was no correlation between IGF-1 or IGFBP-3 levels (corrected for age) and height standard deviation score (SDS) in either non-dialysis or dialysis patients. Study group 2 comprised 19 children (7 on dialysis) who were studied prospectively for 1–2 years to examine the relationship between IGF-1 and IGFBP-3 levels, growth rates and nutritional parameters. Mean values of IGF-1 and IGFBP-3 (corrected for age) did not change over 1-year periods, while height SDS fell by –0.38 ±0.21 SD/year in dialysis patients and by –0.11 ±0.29 SD/year in non-dialysis patients. No significant correlations were found between IGF-1 or IGFBP-3 levels and growth rates or nutritional parameters. Thus growth retardation in children with CRF is not related to circulating levels of IGF-1 or IGFBP-3.     

调节性T细胞在重症肌无力研究中的进展

重症肌无力(MG)为一种由乙酰胆碱受体的抗体介导的、具有T细胞依赖性的自身免疫性疾病。目前研究发现,调节性T细胞(Treg)功能异常在多种自身免疫性疾病包括重症肌无力的发生、发展起着重要作用。文章重点介绍了Treg细胞的特点及其在重症肌无力作用机制方面的进展,旨在能够发现一种对重症肌无力和其他自身免疫性疾病有效的以异常T细胞为基础的治疗方法。